semaglutide and kidney function Effects of with without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic disease in the FLOW trial flow trial semaglutide renal outcomes

Sources & references 1 SURMOUNT () (22.5% ) 2 (5-7% ) 3Retatrutide Phase 2 NEJM 2023 Jastreboff et al

The subjects were categorized based on their baseline BMI and whether they experienced nausea and/or vomiting

Xiaogang Qin, [email protected] These authors have contributed equally to this work This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

lncRNAs or miRNAs could be manipulated by small interfering RNAs, antisense RNAs, RNA mimics, or CRISPR/Cas9 carried by nanoparticle-based delivery systems